Study Reveals 80% of Lung Cancer Deaths in Brazil Linked to Smoking

Regulations by 2FIRSTS.ai
May.17.2024
Study Reveals 80% of Lung Cancer Deaths in Brazil Linked to Smoking
Study at GRELL 2024 reveals 80% of Brazil lung cancer deaths linked to smoking, causing concerns for public health.

According to a report from Brazilian media SBTNEWS on May 16th, a study presented at the Latin American Cancer Epidemiology and Registration Organization annual meeting (GRELL 2024) held by the Cancer Foundation in Switzerland revealed that 80% of male and female lung cancer deaths in Brazil are related to smoking (nicotine dependence). Alfredo Scaff, medical advisor at the Cancer Foundation, stated that the purpose of this study is to present data that can help prevent the disease to society.

 

A standard journalistic translation is: Skaf believes that there is a direct relationship between lung cancer and smoking habits, stating that "strictly speaking, smoking is currently the main cause of cancer worldwide, especially in Brazil.

 

There is controversy surrounding the use of e-cigarettes as a method to quit smoking, according to Scarf. In most cases, he believes it only leads to a habit of addiction to smoking. Scarf has warned that e-cigarettes may further increase the death rate from lung cancer caused by smoking. He also reminds people to be aware that nicotine is the most addictive substance in legal drugs.

 

A study has shown that the annual cost of lung cancer in Brazil reaches up to 9 billion Reais, including direct medical expenses, loss of productivity, and care for patients. However, the tobacco industry only covers 10% of the total expenses related to lung cancer in Brazil, amounting to 125 billion Reais.

 

Skaf pointed out that smoking not only leads to lung cancer but also to tooth decay, damage to the mouth and throat, chronic obstructive pulmonary disease, hypertension, acute myocardial infarction, and stroke. All of these contribute to increased direct costs in the public domain, such as treatment expenses, as well as indirect costs like productivity losses, budget expenditures, and so on.

 

The National Cancer Institute of Brazil predicts that this year there will be 14,000 new cases of lung cancer in women and 18,000 new cases in men. Additionally, the research found that the majority of patients, whether male (63.1%) or female (63.9%), seek medical attention when the disease has already reached an advanced stage. This is a widespread phenomenon across all regions of Brazil.

 

Researchers from the Cancer Foundation analyzed global data from the International Agency for Research on Cancer (IARC) and found that if current smoking patterns continue, the incidence and mortality rates of lung cancer are projected to increase by over 65% and 74% respectively by the year 2040 compared to 2022.

 

In the southern region, smoking is very common. The incidence of lung cancer in the southern region is higher, with 24.14 cases per 100,000 for men and 15.54 cases per 100,000 for women, exceeding the national average of 12.73 cases for men and 9.26 cases for women.

 

The incidence rates of lung cancer in men are lower than the national average in the southern and northeastern regions, while the incidence rates in women in the southern, northeastern, and southeastern regions are 8.27 cases, 8.46 cases, and 8.92 cases per 100,000 people, respectively, also lower than the national average. In all age groups, the male lung cancer mortality rate in the southern region is the highest in the country. According to research, the lung cancer mortality rate in men aged 40-59 in the southern region is 16.03 cases per 100,000 people, while for those aged 60 and above, it is 132.26 cases per 100,000 people.

 

According to information from the Brazilian news agency, Brazil is facing an even more serious issue as many patients are already in the late stages of their illness when seeking treatment. This is not only the case for male patients (63.1%), but also for female patients (63.9%). This is a trend seen across all regions of Brazil.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

GAO Audit Finds Nearly 132,000 FDA Tobacco Applications Waiting an Average 1,266 Days as Nicotine Pouch Pilot Practices Move Into Vape PMTA Reviews
GAO Audit Finds Nearly 132,000 FDA Tobacco Applications Waiting an Average 1,266 Days as Nicotine Pouch Pilot Practices Move Into Vape PMTA Reviews
A U.S. Government Accountability Office audit found that 131,915 tobacco product applications submitted to the FDA since 2018 remained without a final review as of December 31, 2025, with pending applications waiting an average of 1,266 days. GAO also found FDA lacks the data needed to systematically determine whether scientific reviews meet applicable timelines. HHS agreed to upgrade the agency's tracking systems. At the same time, FDA has begun applying lessons from its nicotine pouch PMTA pilot to e-cigarette reviews, while changes to enforcement policy and electronic submissions are making the specific stage of a PMTA increasingly relevant to market access.
FDA
Oct.03
Special Report | How Capital Is Reassessing the Global Tobacco and Modern Nicotine Industry: Lessons from a New York Forum
Special Report | How Capital Is Reassessing the Global Tobacco and Modern Nicotine Industry: Lessons from a New York Forum
Capital is reassessing the global tobacco and modern nicotine industry as heated tobacco, vaping and nicotine pouches reshape demand, profitability and regulation. At the 2026 New Approaches Summit in New York, investors and analysts examined whether smoke-free growth can sustain earnings, how regulation shapes startup value, and whether shareholder engagement can be more effective than divestment. The debate points to a broader shift: tobacco transition is increasingly becoming a capital-allocation, governance and valuation question.
Capital Markets
Oct.05
NAS 2026 | Former FDA Tobacco Chief Mitch Zeller Calls for Shift From “End Game” to “End State”
NAS 2026 | Former FDA Tobacco Chief Mitch Zeller Calls for Shift From “End Game” to “End State”
At the 2026 New Approaches Summit in New York, former FDA Center for Tobacco Products Director Mitch Zeller called for the tobacco harm reduction debate to shift from the traditional “end game” toward defining a desired “end state.” He also highlighted unresolved concerns around dual use, argued that biomarkers of exposure may be more meaningful than cigarettes-per-day in assessing risk reduction, and said nicotine misperceptions remain a major barrier to public health progress.
Sep.25
Indiana Halts Sales of Elf Bar, Lost Mary, MR FOG and iJOY Vapes Under Foreign-Adversary Rules; Some Products Return After Compliance Filings
Indiana Halts Sales of Elf Bar, Lost Mary, MR FOG and iJOY Vapes Under Foreign-Adversary Rules; Some Products Return After Compliance Filings
Indiana's Alcohol and Tobacco Commission (ATC) ordered tobacco certificate holders in September to remove certain vaping products marketed under Elf Bar, Lost Mary, MR FOG, iJOY and other brands from inventory under the state's foreign-adversary product law. The agency later listed 257 MR FOG products and 77 Lost Mary product entries as lawful for sale. The Lost Mary revision expressly stated that compliance evidence had been received for 20 additional products. 2Firsts compliance expert Kurt said potential filings could include e-liquid and ingredient-origin records, U.S. nicotine-analog supply-chain documentation and FDA premarket application status.
Regulations
Oct.08
2Firsts Interview | Cigarette Sales Fall as Smokeless Alternatives Gain in U.S. Convenience Stores, NACS Says
2Firsts Interview | Cigarette Sales Fall as Smokeless Alternatives Gain in U.S. Convenience Stores, NACS Says
Ahead of the 2026 NACS Show, 2Firsts interviewed Chris Rapanick, NACS managing director of research, on changes reshaping the U.S. convenience-store tobacco and nicotine market. NACS data show cigarette sales declining while smokeless alternatives, including nicotine pouches, continue to grow. The interview also examines higher OTP margins, shifting backbar space, weaker store traffic, regulatory uncertainty and NACS’ outlook for 2027, offering a retailer-side view of one of the world’s largest nicotine markets.
Interview
Oct.03
Imperial Brands' NGP Revenue Rises 11.4% in FY2026 but Business Still Posts £63 Million Loss; Zone Reaches 114,000 US Stores as Smokeless Reporting Takes Shape
Imperial Brands' NGP Revenue Rises 11.4% in FY2026 but Business Still Posts £63 Million Loss; Zone Reaches 114,000 US Stores as Smokeless Reporting Takes Shape
Imperial Brands reported an 11.4% increase in next-generation product (NGP) net revenue to £419 million in fiscal 2026, while its adjusted NGP operating loss narrowed to £63 million. European NGP revenue rose 16.8%, while the Americas recorded a 17.1% decline. Global modern oral nicotine volumes increased 27.8%, with US nicotine pouch brand Zone expanding to approximately 114,000 stores. The company also acquired Black Buffalo in the US and Helwit in Sweden, broadening its oral nicotine portfolio. From FY2027, Imperial Brands will adopt a new Smokeless reporting category combining NGP with traditional oral tobacco. On the new basis, FY2026 Smokeless net revenue was £554 million, with adjusted operating profit of £14 million.
company
Nov.18